A 14-year-old female with ADHD and a comorbid history of substance use disorder is started on atomoxetine after the family declines stimulant medications due to abuse concerns. The PMHNP explains atomoxetine's mechanism and required monitoring. Which of the following best describes atomoxetine's pharmacology and the primary safety monitoring concern?